Boehringer Ingelheim site Biberach under new management

Thomas Reith | Boehringer Ingelheim

– Thomas Reith succeeds Dr. Fridtjof Traulsen
– IT expert aims to drive digital transformation

The largest research and development site of Boehringer Ingelheim is getting a new site manager: Thomas Reith will take over from Dr. Fridtjof Traulsen on April 15th in Biberach, who took over the chairmanship of the management of Boehringer Ingelheim Germany GmbH in January. The 57-year-old Reith has been working for the pharmaceutical company for over 20 years, most recently as Head of Information Technology for drug research and development.

“We are very pleased to have been able to recruit an excellent leadership personality as site manager in Thomas Reith,” said Traulsen. Reith is well connected within the company and is particularly committed to the Biberach site. “We especially rely on his many years of experience in information technology.”

In recent years, Reith has intensively dealt with artificial intelligence, big data, and digitalization. He announced his intention to expand Biberach as an innovation and technology location. The digital transformation with all its facets is “a matter close to his heart,” explained the graduate business informatician. Biberach is not only the largest research and development site of Boehringer Ingelheim but also one of the largest pharmaceutical biotechnology locations in Europe.

About Thomas Reith

Thomas Reith was born in 1966 in Göppingen. He grew up in Biberach and attended school there. After earning his diploma in business informatics, he took his first position at the Boehringer subsidiary Thomae in 1991. With his move into scientific informatics in 1996, he began working in the field of research and development (R&D). After various positions in leadership roles in information technology (IT) and biopharmaceuticals, he took over global responsibility for IT for drug research and development in 2010, which he has continuously developed to this day. Reith was one of the co-founders of BI X, Boehringer Ingelheim’s digital lab, in 2017. In 2018, he additionally took on the role of CEO for BI X, alongside his role as Head of IT Research, Development & Medicine.